Efficacy and Safety of IntraSPINE® Associated with Discectomy in the Treatment of Lumbar Disc Herniation.
- Conditions
- Disk Herniated Lumbar
- Interventions
- Device: Insertion of INTRASPINE deviceProcedure: Discectomy
- Registration Number
- NCT03752671
- Lead Sponsor
- Quanta Medical
- Brief Summary
IntraSPINE® is a novel device that, unlike interspinous positioned implants, is unique in being placed more anteriorly in an interlaminar position, closer to the normal center of rotation of the motion segment. Mechanical advantages are thus conferred over more posteriorly positioned devices through the possibility of more physiological 'rocking' type movements in flexion and extension . This enables IntraSPINE® to off-load the facet joints in extension without blocking movement. Having a more anteriorly placed fulcrum also helps control excessive flexion movements by virtue of an improved lever arm in conjunction with an intact posterior tension band.
The underlying hypothesis of this work is that a clinical gain is achieved by adding an IntraSPINE® interlaminar device to discectomy in patients suffering from a lumbar disc herniation. This should result in an improvement in incapacity level and a reduction in pain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 199
Disease-related criteria:
- single segment L4-L5 or L5-S1 lumbar disc hernia identified on imaging (lumbar spine MRI)
- median or posterolateral disc hernia.
- failure of correct medical treatment which has not provided lasting symptom relief absence of contraindications to surgical discectomy and implantation of the IntraSPINE®.
Population related criteria:
- subjects of either sex and over 18 years old
- who have given their free informed signed consent to participate in the study
- patients who are able to respond to the questionnaires and who can communicate in the language of the study country
- and who are affiliated to a social security system or have rights from a social security system.
Disease-related criteria:
- recurrent disc hernia post-discectomy at any level
- foraminal and extra-foraminal disc hernia
- paralysing disc hernia (score of 3/5 or less) and cauda equina syndrome
- any grade of spondylolisthesis
- degenerative scoliosis ≥ 15°
- osteoporosis or Paget's disease
- BMI > 30
- procedure required on more than one vertebral level
- endoscopic microdiscectomy prohibiting insertion of the IntraSPINE®
- chronic infection
- systemic or metabolic disorders
- active ongoing malignant disease (liable to prevent the study being conducted and does not carry a risk of vertebral lysis)
- occupational disorder responsible for the disease Treatment or device-related criteria
- allergy to any of the constituents of the medical device
Population-related criteria:
- past history of spinal procedure.
- withdrawal of consent
- pregnant women
- breast-feeding women
- participation in a clinical study within 3 months before the initial visit.
- drug addiction
- predictable lack of availability during the study. Patients deprived of their freedom or under legal guardianship.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description the IntraSPINE® device associated with discectomy Discectomy - the IntraSPINE® device associated with discectomy Insertion of INTRASPINE device - discectomy alone Discectomy -
- Primary Outcome Measures
Name Time Method Change from Baseline to 12 months of the degree of functional disability associated with lumbar pain will be measured using the Oswestry Disability Index Baseline and 12 months The Oswestry questionnaire provides an assessment of the symptoms and severity of the back pain and repercussions on activities of daily living. The questionnaire contains 10 questions concerning: pain, personal care, carrying loads, walking, seated position, standing position, sleep, sex life, social life and travel. Each question offers six answers with a score of 0 to 6 which the patient must select: a score of 0 represents normal function and a score of 6 represents greatly reduced function.
The score obtained is multiplied by 2 in order to obtain a percentage handicap, with 0% for no handicap and 100% for the greatest handicap. It takes approximately 5 minutes to complete the test.
- Secondary Outcome Measures
Name Time Method The effect of the IntraSPINE® device associated with discectomy versus discectomy alone in the treatment of lumbar disc herniation with regard to recurrence of disc herniation during the study All study period (24 months) recurrence will be defined as the occurrence of disc herniation confirmed by imaging(MRI) or following surgery at the instrumented level in patients undergoing further surgery during the course of the study. This definition enables the inclusion of all hernias (both symptomatic and asymptomatic).
Evolution between inclusion, 1, 6,12 and 24 months post-surgery of the degree of functional disability like symptoms and severity of back pain and repercussions on activities of daily living associated with lumbar pain using the Oswestry Disability Index inclusion, 1 month, 6 months, 12 months and 24 months post-surgery The Oswestry questionnaire provides an assessment of the symptoms and severity of the back pain and repercussions on activities of daily living. The questionnaire contains 10 questions concerning: pain, personal care, carrying loads, walking, seated position, standing position, sleep, sex life, social life and travel. Each question offers six answers with a score of 0 to 6 which the patient must select: a score of 0 represents normal function and a score of 6 represents greatly reduced function.
The score obtained is multiplied by 2 in order to obtain a percentage handicap, with 0% for no handicap and 100% for the greatest handicap. It takes approximately 5 minutes to complete the test.
The Oswestry Disability Index will be measured at inclusion and at 1 month, 6 months, 12 months and 24 months after surgery.Evolution between inclusion, 1 month, 6 months, 12 months and 24 months post-surgery in the two groups with regard to lumbar and radicular pain using a Visual Analogic Scale inclusion, 1 month, 6 months, 12 months and 24 months post-surgery Radicular and lumbar pain will be assessed on a Visual Analogic Scale at inclusion, 1 month, 6 months, 12 months and 24 months post-surgery. The visual analogue scale is a graduated ruler from 0 to 10 cm where 0 indicates that the subject has no pain and 10 cm represents the maximum pain the subject can tolerate. It is a self-assessment scale and is sensitive, reproducible, reliable and validated both in acute pain and chronic pain situations.
Evolution between inclusion, 1month, 6 months, 12 months and 24 months post-surgery in the two groups with regard to quality of life inclusion, 1 month, 6 months, 12 months and 24 months post-surgery Quality of life will be assessed using the 12-Item Short Form Survey (SF-12) score at inclusion, 1 month, 6 months, 12 months and 24 months post-surgery.The SF-12 test is a shortened version of the "Medical Outcomes Study Short-Form General Health Survey" (SF 36) which only includes 12 of the 36 questions. The SF 12 provides two scores: a mental and social quality of life score and a physical quality of life score. The SF-12 summary scores range from 0 to 100 with higher scores representing better self-reported health
Evolution between inclusion, 12 months and 24 months post-surgery in the two groups with regard to sagittal alignement inclusion, 12 months and 24 months post-surgery Sagittal alignment will be measured at inclusion, 12 months and 24 months post-surgery by lateral x-ray (full spine).
Evolution between inclusion, 12 months and 24 months post-surgery in the two groups with regard to disc height inclusion, 12 months and 24 months post-surgery Disc height (anterior and posterior) will be measured at inclusion, 12 months and 24 months post-surgery based on full-spine x-rays
Evolution between inclusion, 1 month, 6 months, 12 months and 24 months in the two groups with regard to neurological and motor status inclusion, 1 month, 6 months, 12 months and 24 months Neurological and motor status will be assessed at inclusion, 1 month, 6 months, 12 months and 24 months post-surgery using the AIS scale (ASIA "American Spinal Injury Association" Impairment Scale): the section concerning ponytail syndrome will be included in the evaluation.The AIS measurement scale (ASIA "American Spinal Injury Association" Impairment Scale), based on the Frankel Scale is a scale administered by the clinician used to classify the severity of the lesions of patients who have spinal lesions. It is a 5 point ordinal scale and classifies people from A "complete lesions" to E "normal sensory and motor functions"
Time to resumption of work post-surgery 1 month, 6 months, 12 months and 24 months post-surgery The time to resumption of work following surgery will be evaluated in terms of the number of days between hospitalisation and resumption of activity and by the number of days off work due to the disease for which the operation was performed during the 24-month follow-up period.
Rates of further surgery at the level of the implant during the study All study period (24 months) The revision surgery rate (Re intervention or further surgery) . Further surgery throughout the duration of the study is defined as a second operation at the instrumented level (level of the implant performed ) during the course of the study, regardless of reason (i.e. infectious or mechanical): revision, implant removal (explantation), fusion, need for additional fixation, or any surgery affecting any part of the device or relating to any associated complications
The number of adverse events (AE) reported, classified by type and organ. All study period (24 months) The safety and tolerability end points will be will be as follows:
The number of adverse events (AE) reported, classified by type and organ.The number of serious adverse events (SAE) reported, classified by type and organ. All study period (24 months) The safety and tolerability end points will be will be as follows:
The number of serious adverse events (SAE) reported, classified by type and organ.Integrity of the implant: migration or wear All study period (24 months) The safety and tolerability end points will be will be as follows:
Integrity of the implant: migration or wear.The peroperative complication rate. All study period (24 months) The safety and tolerability end points will be will be as follows:
The peroperative complication rate.The short and long term postoperative complication rate. All study period (24 months) The safety and tolerability end points will be will be as follows:
The short and long term postoperative complication rate.
Trial Locations
- Locations (1)
George Pompidou European Hospital
🇫🇷Paris, France